Pharma
June 11-12, 2014, NJ Expo Center, Edison, NJ.
Microbes are not only a rich source of disease, but also a rich source of medicines, and experts think many life-saving compounds produced by as-yet-unnamed bacteria are awaiting discovery. But they don’t always give up their secrets easily. Researchers must know where to look to find promising bacteria, and how to get them to grow in the lab, the traditional route to identifying potentially valuable molecules they produce.
NYU Langone Medical Center Establishes Office of Therapeutics Alliances to Accelerate Drug Discovery
NYU Langone Medical Center has established a new drug discovery accelerator, the Office of Therapeutics Alliances (OTA). OTA is an innovative, nimble program that advances the discovery of novel therapeutic projects by combining the scientific strengths of NYU Langone investigators in dissecting disease pathways with the expertise of external professional drug discovery and development partners in the biopharma industry.
Johnson & Johnson Innovation is first collaborator.
Killian Award recipient Stephen Lippard describes his work on platinum-based chemotherapy agents
As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety and drug interactions — without using animals. The development of “chemosynthetic livers,” which could dramatically alter how drugs are made, was presented at the 247th National Meeting & Exposition of the American Chemical Society (ACS), the world’s largest scientific society.
William K. Warren Foundation endows Warren Family Research Center for Drug Discovery and Development
The William K. Warren Foundation of Tulsa, Okla., has made a $3.5 million gift to the University of Notre Dame that, combined with a previous gift valued at $6.5 million, will endow the creation of The Warren Family Research Center for Drug Discovery and Development in the College of Science.
Scientists from the University of Sheffield have developed a novel antibody-based therapy which targets the progression of life threatening kidney fibrosis.
Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find—relatively quickly and cheaply—antibodies that have a desired effect on cells. The TSRI scientists used the technique to discover two antibodies that protect human cells from a cold virus.
